DocGo Inc

DCGO remains entrenched in a Stage 4 decline with a persistent sequence of lower highs and lower lows under declining EMAs. The medium-term bias is Bearish, reinforced by pattern continuation and lack of stabilization, while short-term bounce attempts have failed to reclaim EMAs. Execution timing is unfavorable for selling now, so we Trim exposure on rallies into the 9EMA–20EMA zone and await further confirmation of downtrend continuation.

• ↑Upgraded 2026 revenue guidance to $300–315M.
• ↑Non-migrant mobile health revenues jumped 78% YoY.
• ↓Q2 revenue declined 8.8% YoY to $73.4M.